Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1891871661
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
15655 Cypress Wood Medical Dr Ste 100
Houston, TX, 77014
Phone (713) 442-1700
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
1,753 services
Medicare patients, 2024
19
Average age 73
Drug cost, 2024
$9.5M
3,378 prescriptions
Company payments, 2025
$153
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tri T Vu was code 99214 (office e&m - established), 18 times for 12 patients. In total Tri T Vu billed 1,753 services in 29 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 18 | 12 | $87.11 | $1,568 |
By year: 2022 $62K for 3,393 services; 2023 $35K for 2,286 services; 2024 $77K for 1,753 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tri T Vu prescribed most often to Medicare patients was Anastrozole, with 294 prescriptions and refills. In total Tri T Vu wrote 3,378 Medicare prescriptions that cost $9.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 294 | 598 | 70 | $9,910 |
| Eliquis Apixaban | 234 | 328 | 45 | $172K |
| Ondansetron Hcl Generic | 199 | 199 | 90 | $1,423 |
| Dexamethasone Generic | 154 | 171 | 58 | $822 |
| Olanzapine Generic | 136 | 140 | 50 | $104 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 125 | 126 | 58 | $2,370 |
| Prednisone Generic | 110 | 113 | 35 | $456 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 109 | 109 | 80 | $974 |
| Brukinsa Zanubrutinib | 78 | 78 | 11 | $1.2M |
| Lorazepam Generic | 76 | 78 | 32 | $123 |
| Revlimid Lenalidomide | 75 | 75 | 11 | $972K |
| Abiraterone Acetate Generic | 67 | 67 | 15 | $264K |
| Xtandi Enzalutamide | 67 | 67 | Under 11 | $948K |
| Potassium Chloride Generic | 63 | 95 | 20 | $1,189 |
| Calquence Acalabrutinib Maleate | 59 | 59 | Under 11 | $899K |
Brand drugs: 890 claims; generic drugs: 2,488 claims; opioid claims: 241.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tri T Vu $153 ($153 in general payments such as food, travel and fees) from 3 companies. The largest payer was Celgene Corporation with $153.
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation BMY | 3 | $153 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.